The epidermal growth factor receptor (EGRF) in lung cancer

In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovere...

Descripción completa

Detalles Bibliográficos
Autores principales: Carcereny, Enric, Morán, Teresa, Capdevila, Laia, Cros, Sara, Vilà, Laia, de los Llanos Gil, Maria, Remón, Jordi, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366432/
https://www.ncbi.nlm.nih.gov/pubmed/25810955
http://dx.doi.org/10.1186/s40247-015-0013-z
Descripción
Sumario:In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.

Ejemplares similares